AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35836830 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF
Number of subjects: 19
Study 35836830 — intervention group
Group type: COMPARATOR
Intervention: ATO
Number of subjects: 19
Study 33434408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 1 mg
Number of subjects: 21
Study 33434408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 21
Study 33434408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 25 mg
Number of subjects: 21
Study 33434408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 25 mg (Cohort B)
Number of subjects: 21
Study 33434408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Cohort A)
Number of subjects: 21
Study 33434408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Cohort B)
Number of subjects: 21
Study 32114808 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression (ASD)
Number of subjects: 2217
Study 32114808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acromioclavicular joint excision (ACJE)
Number of subjects: 2217
Study 32114808 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair (RCR)
Number of subjects: 2217
Study 34762378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for regulating spleen and stomach combined with aspirin enteric‐coated tablets
Number of subjects: 68
Study 34762378 — intervention group
Group type: COMPARATOR
Intervention: Aspirin enteric‐coated tablets (100 mg once daily)
Number of subjects: 68
Study 32513836 — intervention group
Group type: EXPERIMENTAL
Intervention: pTVG-AR vaccine with or without GM-CSF adjuvant
Number of subjects: 40
Study 32513836 — intervention group
Group type: EXPERIMENTAL
Intervention: pTVG-AR vaccine
Number of subjects: 40
Study 35616018 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ET)
Number of subjects: 2130
Study 34725379 — intervention group
Group type: EXPERIMENTAL
Intervention: High current density tACS (1 mA; 10 Hz and 20 Hz; 0.32 mA/cm2) for 20 min over bilateral sensorimotor areas
Number of subjects: 30
Study 34725379 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 30
Study 35867853 — intervention group
Group type: COMPARATOR
Intervention: Oral tianeptine (50 mg)
Number of subjects: 23
Study 35867853 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tianeptine (500 to 2000 ng/ml)
Number of subjects: 23
Study 34843346 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy, delivered in a massed format (daily sessions across 2 weeks)
Number of subjects: 0
Study 32763196 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS4 blood-based diagnostic test
Number of subjects: 702
Study 36306151 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 88
Study 36306151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Number of subjects: 88
Study 36306151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 88
Study 36306151 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Liraglutide, Diet, Sitagliptin)
Number of subjects: 88
Study 34402199 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy intervention
Number of subjects: 842
Study 34402199 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 842
Study 32219359 — intervention group
Group type: EXPERIMENTAL
Intervention: Apabetalone (100 mg orally twice daily)
Number of subjects: 2425
Study 32219359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2425
Study 35421017 — intervention group
Group type: EXPERIMENTAL
Intervention: d-mannose
Number of subjects: 71
Study 35421017 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 71
Study 33847018 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐PRF
Number of subjects: 20
Study 33847018 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐PRF+
Number of subjects: 20
Study 33847018 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 36177972 — intervention group
Group type: EXPERIMENTAL
Intervention: Forehead cooling (pre-frontal cortex cooling)
Number of subjects: 34
Study 36177972 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study 34769849 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletics Injury Prevention Programme (AIPP) 2/week
Number of subjects: 840
Study 34769849 — intervention group
Group type: COMPARATOR
Intervention: Regular training (Control)
Number of subjects: 840
Study 32165032 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based therapy (DVD)
Number of subjects: 44
Study 32165032 — intervention group
Group type: COMPARATOR
Intervention: In-person therapist
Number of subjects: 44
Study 36128663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg intravenously) every 4 weeks for 24 weeks
Number of subjects: 36
Study 36128663 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 24 weeks
Number of subjects: 36
Study 36128663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg intravenously)
Number of subjects: 36
Study 36128663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 33389776 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 117
Study 33389776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 32713072 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared radiation (NIR) application to skin
Number of subjects: 11
Study 32713072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NIR application)
Number of subjects: 11
Study 32423329 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HIR (Hypoperfusion Intensity Ratio)
Number of subjects: 123
Study 32423329 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CBV Index (Cerebral Blood Volume)
Number of subjects: 123
Study 32423329 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h HIR
Number of subjects: 123
Study 32423329 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h CBV Index
Number of subjects: 123
Study 32423329 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h CBV Index for smaller than predicted infarcts
Number of subjects: 123
Study 36288924 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA-guided management
Number of subjects: 250
Study 36288924 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 250
Study 32735952 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hyperglycaemia (mean blood glucose: 321 ± 29 mg/dL)
Number of subjects: 18
Study 32735952 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia (mean blood glucose: 138 ± 34 mg/dL)
Number of subjects: 18
Study 33220353 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 19
Study 33220353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 32583994 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms misoprostol per rectally half an hour before surgery
Number of subjects: 50
Study 32583994 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study 34887241 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MRI
Number of subjects: 100
Study 34887241 — intervention group
Group type: COMPARATOR
Intervention: 1.5T MRI
Number of subjects: 100
Study 33449070 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality research (Level I) from randomized, controlled trials
Number of subjects: 2920
Study 33449070 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate quality research (Level II) from observational studies
Number of subjects: 2920
Study 33449070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low quality research (Level III) from expert opinion
Number of subjects: 2920
Study 33449070 — intervention group
Group type: COMPARATOR
Intervention: Original guidelines vs. updated guidelines for Clostridium difficile
Number of subjects: 2920
Study 33449070 — intervention group
Group type: COMPARATOR
Intervention: Original guidelines vs. updated guidelines for candidiasis
Number of subjects: 2920
Study 33449070 — intervention group
Group type: COMPARATOR
Intervention: Original guidelines vs. updated guidelines for coccidiomycosis
Number of subjects: 2920
Study 34642832 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Assessment Scale (RAS)
Number of subjects: 56
Study 33428583 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (D) 1500 mg/tremelimumab (T) 75 mg (intravenously every 4 weeks without SBRT)
Number of subjects: 18
Study 33428583 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-sensitizing SBRT to one selected tumor site (9 Gy × 3 fractions) followed by D/T
Number of subjects: 18
Study 33428583 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled efficacy of D/T±SBRT in 15 RECIST evaluable patients
Number of subjects: 18
Study 33428583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in arm A
Number of subjects: 18
Study 33428583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in arm B
Number of subjects: 18
Study 33428583 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in peripheral blood lymphocyte and TILs
Number of subjects: 18
Study 35989575 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger self‐management training (ASMT)
Number of subjects: 54
Study 33984151 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib and radiotherapy followed by adjuvant veliparib and temozolomide
Number of subjects: 125
Study 33984151 — intervention group
Group type: COMPARATOR
Intervention: Concurrent temozolomide and radiotherapy followed by adjuvant temozolomide
Number of subjects: 125
Study 32124520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 503
Study 32124520 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 503
Study 35562720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild anemia (Hb 10.0-11.0 g/dL)
Number of subjects: 11370
Study 35562720 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate anemia (Hb 7.0-10.0 g/dL)
Number of subjects: 11370
Study 35562720 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe anemia (Hb < 7.0 g/dL)
Number of subjects: 11370
Study 35562720 — intervention group
Group type: COMPARATOR
Intervention: Mild or moderate anemia
Number of subjects: 11370
Study 35562720 — intervention group
Group type: COMPARATOR
Intervention: No anemia
Number of subjects: 11370
Study 35562720 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia severity (mild, moderate, severe)
Number of subjects: 11370
Study 32268592 — intervention group
Group type: EXPERIMENTAL
Intervention: Taekwondo training (5 times a week for 16 weeks)
Number of subjects: 20
Study 32268592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 32860075 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD1 therapy (discontinued due to prolonged remission or unacceptable toxicity)
Number of subjects: 40
Study 32860075 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for predicting progression-free survival (PFS)
Number of subjects: 40
Study 32860075 — intervention group
Group type: EXPERIMENTAL
Intervention: Training set performance of machine learning algorithm
Number of subjects: 40
Study 35013893 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial ablation (A > V)
Number of subjects: 90
Study 35013893 — intervention group
Group type: COMPARATOR
Intervention: Ventricular ablation (V > A)
Number of subjects: 90
Study 34602470 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat/glycemic index diet (HIGH)
Number of subjects: 49
Study 34602470 — intervention group
Group type: COMPARATOR
Intervention: Low saturated fat/glycemic index diet (LOW)
Number of subjects: 49
Study 32764081 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (one session of Western medical acupuncture treatment in addition to standard treatment)
Number of subjects: 171
Study 32764081 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment according to Norwegian guidelines
Number of subjects: 171
Study 35703877 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 61
Study 35703877 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 61
Study 35703877 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 34500081 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (0.5 ?g/kg/min)
Number of subjects: 52
Study 34500081 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (0.2-0.5 ?g/kg/min)
Number of subjects: 52
Study 36476466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac postoperatively and 3 days of oral ketorolac on discharge
Number of subjects: 48
Study 36476466 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care pain protocol involving oxycodone-acetaminophen 5 to 325 on discharge
Number of subjects: 48
Study 34247414 — intervention group
Group type: EXPERIMENTAL
Intervention: Irritable bowel syndrome (IBS)
Number of subjects: 1322
Study 34247414 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dyspepsia (FD)
Number of subjects: 1322
Study 34247414 — intervention group
Group type: COMPARATOR
Intervention: Any sleep disturbance
Number of subjects: 1322
Study 32599215 — intervention group
Group type: EXPERIMENTAL
Intervention: INSPIRE program (Internet and social media-based intervention)
Number of subjects: 2578
Study 34895160 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose citrate (4.5 mmol/L)
Number of subjects: 35
Study 34895160 — intervention group
Group type: COMPARATOR
Intervention: Low dose citrate (2.5 mmol/L)
Number of subjects: 35
Study 34895160 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high and low citrate)
Number of subjects: 35
Study 33119572 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (OL@‐OR@ smartphone app)
Number of subjects: 726
Study 33119572 — intervention group
Group type: COMPARATOR
Intervention: Control version of the intervention
Number of subjects: 726
Study 35197332 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group setting intervention divided into five sessions (self-care as a leader, leadership attitudes and behaviour, motives, needs and stressors of employees, strengthen the resource 'team', reflection and focus groups)
Number of subjects: 93
Study 35197332 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group setting intervention
Number of subjects: 93
Study 35197332 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 93
Study 34053801 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with epinephrine 1:100,000
Number of subjects: 139
Study 34053801 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with epinephrine 1:100,000
Number of subjects: 139
Study 32409981 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg IV tramadol
Number of subjects: 0
Study 32409981 — intervention group
Group type: COMPARATOR
Intervention: 4 mg IV morphine
Number of subjects: 0
Study 32409981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34694261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel blockers (CCB)
Number of subjects: 5020
Study 34694261 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 5020
Study 32074324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored group (RTM)
Number of subjects: 33
Study 32074324 — intervention group
Group type: COMPARATOR
Intervention: Nonmentored group
Number of subjects: 33
Study 32074324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 34982007 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispot technique (20 ms exposure time)
Number of subjects: 0
Study 34982007 — intervention group
Group type: COMPARATOR
Intervention: Single-spot technique (150 ms exposure time)
Number of subjects: 0
Study 34001407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (80 minutes applied in addition to standard oral care)
Number of subjects: 32
Study 33072188 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (20 grams total, with a 15-minute loading dose followed by a 24-hour maintenance infusion)
Number of subjects: 1126
Study 33072188 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered in the same manner as magnesium sulfate)
Number of subjects: 1126
Study 33657760 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intra‐articular (IA) infusion analgesia
Number of subjects: 72
Study 33657760 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 72
Study 33657760 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia (EA)
Number of subjects: 72
Study 631335334 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 726
Study 631335334 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (control group)
Number of subjects: 726
Study 34213086 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention for 8 weeks (n=21)
Number of subjects: 41
Study 34213086 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control for 8 weeks (n=20)
Number of subjects: 41
Study 34213086 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Treatment Expectancy Scale (TES)
Number of subjects: 41
Study 34000325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg.kg‐1
Number of subjects: 100
Study 34000325 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 μg.kg‐1
Number of subjects: 100
Study 35174670 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise program via Zoom, 3 times a week for 12 weeks
Number of subjects: 28
Study 35174670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telerehabilitation)
Number of subjects: 28
Study 33743321 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk evaluation score for vitamin D insufficiency
Number of subjects: 2280
Study 33743321 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk evaluation score for vitamin D deficiency
Number of subjects: 2280
Study 33743321 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal points of change for risk scores
Number of subjects: 2280
Study 33957103 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based care plus clinical decision support system (CDSS)
Number of subjects: 38
Study 33957103 — intervention group
Group type: COMPARATOR
Intervention: Team-based care alone
Number of subjects: 38
Study 33261915 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate nicotine reduction condition (0.4 mg/g nicotine cigarettes)
Number of subjects: 957
Study 33261915 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual nicotine reduction condition (15.5 to 0.4 mg/g)
Number of subjects: 957
Study 33261915 — intervention group
Group type: COMPARATOR
Intervention: Control condition (15.5 mg/g)
Number of subjects: 957
Study 33261915 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 957
Study 33261915 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants interested in quitting
Number of subjects: 957
Study 33261915 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 957
Study 33261915 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with greater dependence scores
Number of subjects: 957
Study 33261915 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged 18–24
Number of subjects: 957
Study 33933731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss intervention for 8 weeks
Number of subjects: 52
Study 33933731 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (control group)
Number of subjects: 52
Study 34214095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotasiil (3 doses)
Number of subjects: 3508
Study 34214095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3508
Study 36069871 — intervention group
Group type: EXPERIMENTAL
Intervention: Litifilimab 450 mg
Number of subjects: 132
Study 36069871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 32019434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa beverage
Number of subjects: 60
Study 32019434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa and UBF beverage
Number of subjects: 60
Study 32589851 — intervention group
Group type: EXPERIMENTAL
Intervention: MiYoga (n=21)
Number of subjects: 42
Study 32589851 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n=21)
Number of subjects: 42
Study 35075494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ningmitai capsule (1.52 g, three times daily)
Number of subjects: 102
Study 35075494 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 34325077 — intervention group
Group type: EXPERIMENTAL
Intervention: R-PDT: PDT with riboflavin
Number of subjects: 80
Study 34325077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu-PDT: PDT with curcumin
Number of subjects: 80
Study 34325077 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG: laser application
Number of subjects: 80
Study 34325077 — intervention group
Group type: COMPARATOR
Intervention: Control group: resin-modified glass ionomer restoration with no treatment
Number of subjects: 80
Study 35694924 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory training (frequent short-term sniffing various odors) for 4 months, performed twice a day
Number of subjects: 37
Study 35694924 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (not specified)
Number of subjects: 37
Study 35694924 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory training
Number of subjects: 37
Study 32487881 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient rankings of adverse events (AEs) and adverse symptoms (ASs) severity
Number of subjects: 0
Study 32487881 — intervention group
Group type: COMPARATOR
Intervention: Physician rankings of adverse events (AEs) and adverse symptoms (ASs) severity
Number of subjects: 0
Study 32487881 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making and quality-of-life outcomes
Number of subjects: 0